NCT07166354

Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Applied Biology, Inc. · Industry
• Sex: All
• Age: 30 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Clinical Study to Assess the Safety and Efficacy of CS-002 (mTOR inhibitor) as a treatment for Canities (Grey Hair)

Detailed description

CS-002 is a small molecule that is an mTOR ("mammalian target of rapamycin ") inhibitor. In vitro and a small pilot study demonstrated re-pigmentation of grey hair following CS-002 application. The aim of this study is to assess the safety and efficacy of CS-002 as a treatment for grey hair.

Conditions

• Canities
• Grey Hair

Interventions

Type	Name	Description
DRUG	CS-002	CS-002 Topical Treatment
DRUG	Placebo Topical Solution	Placebo Topical Solution

Timeline

• Start date: 2025-10-01
• Primary completion: 2027-06-15
• Completion: 2027-09-15
• First posted: 2025-09-10
• Last updated: 2025-09-10